Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of LYB005 recombinant RSV vaccine (CHO cell) in adults ≥60 years
ChiCTR2500113441Phase 2Completed
- Sponsor
- Hubei Center for Disease Control and Prevention
- Start
- Nov 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LYB005 in respiratory syncytial virus disease (RSV) and acute respiratory illness (ARI) (7 arms), sponsored by Hubei Center for Disease Control and Prevention. Primary endpoint: Serum neutralizing antibody GMT and GMFR against RSV-A and RSV-B at 30 days post-vaccination. Started Nov 2025; status: completed.
02
Drugs
LYB005
03
Conditions
respiratory syncytial virus disease (RSV)acute respiratory illness (ARI)
Beyond the preview
Go deeper on ChiCTR2500113441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113441.